Reagenzgläser
Vesalius Biocapital

A European life sciences venture capital investor

.

About us

Vesalius Biocapital is a European life sciences venture capital investor. The active fund Vesalius Biocapital III had a final closing in May 2019 with € 120 million in commitments.

We are investing in appealing, later-stage companies in drug development, medical devices & diagnostics and eHealth / mHealth, predominantly in Europe. Our portfolio companies address unmet medical & market needs and operate on the basis of strong intellectual property protection.

 

Fund 3

Vesalius Biocapital III

Vintage 2017 - € 120 million assets under management. In investment mode

read more

 

News

Vesalius News

Memo Therapeutics: Frits v. Alphen CDO
read more
Phase II Clinical Trial of Potravitug
read more
Study in COPD-related sarcopenia
read more
.

xxnoxx_zaehler